Methods of treating inflammation in airways

Information

  • Patent Grant
  • 8534291
  • Patent Number
    8,534,291
  • Date Filed
    Wednesday, May 31, 2006
    18 years ago
  • Date Issued
    Tuesday, September 17, 2013
    11 years ago
Abstract
This relates to treating an asthmatic lung and more particularly, relates to advancing a treatment device into the lung and treating the lung with the device. This also includes additional steps of treating the airway wall, applying energy or heat to the airway wall in an asthmatic lung.
Description
BACKGROUND OF THE INVENTION

The invention relates to a method of treating a lung having at least one symptom of reversible obstructive pulmonary disease, and more particularly, the invention relates to advancing a treatment device into the lung and treating the lung with the device to at least reduce the ability of the lung to produce at least one of the symptoms of reversible obstructive pulmonary disease. The invention includes additional steps that reduce the ability of the lung to produce at least one of the symptoms of reversible obstructive pulmonary disease and to reduce the resistance to the flow of air through a lung.


Reversible obstructive pulmonary disease includes asthma and reversible aspects of chronic obstructive pulmonary disease (COPD). Asthma is a disease in which (i) bronchoconstriction, (ii) excessive mucus production, and (iii) inflammation and swelling of airways occur, causing widespread but variable airflow obstruction thereby making it difficult for the asthma sufferer to breathe. Asthma is a chronic disorder, primarily characterized by persistent airway inflammation. However, asthma is further characterized by acute episodes of additional airway narrowing via contraction of hyper-responsive airway smooth muscle.


The reversible aspects of COPD generally describe excessive mucus production in the bronchial tree. Usually, there is a general increase in bulk (hypertrophy) of the large bronchi and chronic inflammatory changes in the small airways. Excessive amounts of mucus are found in the airways and semisolid plugs of mucus may occlude some small bronchi. Also, the small airways are narrowed and show inflammatory changes. The reversible aspects of COPD include partial airway occlusion by excess secretions, and airway narrowing secondary to smooth muscle contraction, bronchial wall edema and inflation of the airways


In asthma, chronic inflammatory processes in the airway play a central role in increasing the resistance to airflow within the lungs. Many cells and cellular elements are involved in the inflammatory process, particularly mast cells, eosinophils T lymphocytes, neutrophils, epithelial cells, and even airway smooth muscle itself. The reactions of these cells result in an associated increase in the existing sensitivity and hyper-responsiveness of the airway smooth muscle cells that line the airways to the particular stimuli involved.


The chronic nature of asthma can also lead to remodeling of the airway wall (i.e., structural changes such as thickening or edema) which can further affect the function of the airway wall and influence airway hyper-responsiveness. Other physiologic changes associated with asthma include excess mucus production, and if the asthma is severe, mucus plugging, as well as ongoing epithelial denudation and repair. Epithelial denudation exposes the underlying tissue to substances that would not normally come in contact with them, further reinforcing the cycle of cellular damage and inflammatory response.


In susceptible individuals, asthma symptoms include recurrent episodes of shortness of breath (dyspnea), wheezing, chest tightness, and cough. Currently, asthma is managed by a combination of stimulus avoidance and pharmacology.


Stimulus avoidance is accomplished via systematic identification and minimization of contact with each type of stimuli. It may, however, be impractical and not always helpful to avoid all potential stimuli.


Asthma is managed pharmacologically by: (1) long term control through use of anti-inflammatories and long-acting bronchodilators and (2) short term management of acute exacerbations through use of short-acting bronchodilators. Both of these approaches require repeated and regular use of the prescribed drugs. High doses of corticosteroid anti-inflammatory drugs can have serious side effects that require careful management. In addition, some patients are resistant to steroid treatment. The difficulty involved in patient compliance with pharmacologic management and the difficulty of avoiding stimulus that triggers asthma are common barriers to successful asthma management.


Asthma is a serious disease with growing numbers of sufferers. Current management techniques are neither completely successful nor free from side effects.


Accordingly, it would be desirable to provide an asthma treatment which improves airflow without the need for patient compliance.


In addition to the airways of the lungs, other body conduits such as the esophagus, ureter, urethra, and coronary arteries, are also subject to periodic reversible spasms that produce obstruction to flow.


SUMMARY OF THE INVENTION

The present invention relates to methods for treating a lung, preferably having at least one symptom of reversible obstructive pulmonary disease, comprising the steps of advancing a treatment device into the lung and treating the lung with the device to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease and to decrease the resistance to the flow of air through the lung.


A variation of the invention includes the method described above further comprising the step of locating one or more treatment sites within an airway of the lung, selecting at least one of the treatment sites and treating at least one of the treatment sites selected in the selecting step. The invention may further include performing the steps while the lung is experiencing at least one symptom of either natural or artificially induced reversible obstructive pulmonary disease.


A further variation of the invention includes the method described above and further includes the steps of testing the lung for at least one pre-treatment pulmonary function value prior to the treating step, and re-testing the lung for at least one post-treatment pulmonary function value subsequent to the treating step.


A further variation of the invention includes the method described above further comprising identifying treatment sites within the airway being highly susceptible to either airway inflammation, airway constriction, excessive mucus secretion, or any other symptom of reversible obstructive pulmonary disease.


Another variation of the invention includes the method described above and the additional step of stimulating the lung to produce at least one artificially induced symptom of reversible obstructive pulmonary disease. The invention may further comprise the step of evaluating the results of the stimulating step.


Another variation of the invention includes the method described above where treating at least airway tissue within the lung further comprises the step of determining the effect of the treatment by visually observing the airway for blanching of airway tissue.


Another variation of the invention includes the method described above where treating at least airway tissue at a treatment site within the lung further comprises the step of monitoring electrical impedance of tissue at one or more points.


Another variation of the invention includes the method described above where treating the lung includes sub-mucosal treatment of at least airway tissue in the lung.


Another variation of the invention includes the method described above where the treating step includes treating the lung by depositing a radioactive substance in at least one treatment site within the lung.


Another variation of the invention include the method described above further including the step of scraping tissue from a wall of an airway within the lung prior to the treating step. The invention may further comprise depositing a substance on the scraped wall of the airway.


Another variation of the invention includes the method described above where the treating step uses a modality selected from the group consisting of mechanical, chemical, radio frequency, radioactive energy, heat, and ultrasound.


Another variation of the invention includes the method described above further comprising pre-treating the lung to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease prior to the treating step, where at least one parameter of the pre-treating step is lesser than at least one parameter of the treating step.


Another variation of the invention comprises the method described above where the treating step includes separating the treating step into stages to reduce the healing load on the lung. The separating step may comprise treating different regions of the lung at different times or dividing the number of treatment sites into a plurality of groups of treatment sites and treating each group at a different time.


Another variation of the invention includes the method described above further comprising sensing movement of the lung and repositioning the treatment device in response to said sensing step.


Another variation of the invention includes the method described above further comprising reducing the temperature of lung tissue adjacent to a treatment site.


Another variation of the invention includes the method described above further comprising the step of providing drug therapy, exercise therapy, respiratory therapy, and/or education on disease management techniques to further reduce the effects of reversible obstructive pulmonary disease.


The invention further includes the method for reversing a treatment to reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease comprising the step of stimulating re-growth of smooth muscle tissue in the lung.


The invention further includes the method of evaluating an individual having reversible obstructive pulmonary disease as a candidate for a procedure to reduce the ability of the individual's lung to produce at least one reversible obstructive pulmonary disease symptom by treating an airway within the lung of the individual, the method comprising the steps of assessing the pulmonary condition of the individual, comparing the pulmonary condition to a corresponding predetermined state; and evaluating the individual based upon the comparing step. The method may additionally comprise the steps of performing pulmonary function tests on the individual to obtain at least one pulmonary function value, comparing the at least one pulmonary function value to a corresponding predetermined pulmonary function value, and evaluating the individual based upon the comparing step.


The invention further comprises a method of evaluating the effectiveness of a procedure to reduce the ability of lung to produce at least one symptom of reversible obstructive pulmonary disease previously performed on an individual having reversible obstructive pulmonary disease, the method comprising the steps of assessing the pulmonary condition of the individual, comparing the pulmonary condition to a corresponding predetermined state; and evaluating the effectiveness of the procedure based upon the comparing step. The method may additionally comprise the steps of performing pulmonary function tests on the individual to obtain at least one pulmonary function value, treating the lung to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease, performing post-procedure pulmonary function tests on the individual to obtain at least one post-procedure pulmonary function value; and comparing the pulmonary function value with the post-procedure pulmonary function value to determine the effect of the treating step.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention will now be described in greater detail with reference to the various embodiments illustrated in the accompanying drawings:



FIG. 1. is a cross sectional view of an airway in a healthy lung.



FIG. 2. shows a section through a bronchiole having an airway diameter smaller than that shown in FIG. 1.



FIG. 3 illustrates the airway of FIG. 1 in which the smooth muscle 14 has hypertrophied and increased in thickness causing reduction of the airway diameter.



FIG. 4 is a schematic side view of the lungs being treated with a treatment device 38 as described herein.





DETAILED DESCRIPTION

The invention relates to methods for improving airflow through the airways of a lung having reversible obstructive pulmonary disease. It is intended that the invention is applicable to any aspect of reversible obstructive pulmonary disease, including but not limited to asthma. One way of improving airflow is to decrease the resistance to airflow within the lungs. There are several approaches to reducing this resistance, including but not limited to reducing the ability of the airway to contract, increasing the airway diameter, reducing the inflammation of airway tissues, and/or reducing the amount of mucus plugging of the airway. The present invention includes advancing a treatment device into the lung and treating the lung to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease. The following is a brief discussion of some causes of increased resistance to airflow within the lungs and the inventive treatment of the invention described herein. As such, the following discussion is not intended to limit the aspects or objective of the inventive method as the inventive method may cause physiological changes not described below but such changes still contributing to reducing or eliminating at least one of the symptoms of reversible obstructive pulmonary disease.


Reducing the Ability of the Airway to Contract


The inventive treatment reduces the ability of the airways to narrow or to reduce in diameter due to airway smooth muscle contraction. The inventive treatment uses a modality of treatments including, but not limited to the following: chemical, radio frequency, radioactivity, heat, ultrasound, radiant, laser, microwave, or mechanical energy (such as in the form of cutting, punching, abrading, rubbing, or dilating). This treatment reduces the ability of the smooth muscle to contract thereby lessening the severity of an asthma attack. The reduction in the ability of the smooth muscle to contract may be achieved by treating the smooth muscle itself or by treating other tissues which in turn influence smooth muscle contraction or the response of the airway to the smooth muscle contraction. Treatment may also reduce airway responsiveness or the tendency of the airway to narrow or to constrict in response to a stimulus.


The amount of smooth muscle surrounding the airway can be reduced by exposing the smooth muscle to energy which either kills the muscle cells or prevents these cells from replicating. The reduction in smooth muscle reduces the ability of the smooth muscle to contract and to narrow the airway during a spasm. The reduction in smooth muscle and surrounding tissue has the added potential benefit of increasing the caliber or diameter of the airways, this benefit reduces the resistance to airflow through the airways. In addition to the use of debulking smooth muscle tissue to open up the airways, the device used in the present invention may also eliminate smooth muscle altogether by damaging or destroying the muscle. The elimination of the smooth muscle prevents the contraction or spasms of hyper-reactive airways of a patient having reversible obstructive pulmonary disease. By doing so, the elimination of the smooth muscle may reduce some symptoms of reversible obstructive pulmonary disease.


The ability of the airway to contract can also be altered by treatment of the smooth muscle in particular patterns. The smooth muscle is arranged around the airways in a generally helical pattern with pitch angles ranging from about −38 to about +38 degrees. Thus, the treatment of the smooth muscle in appropriate patterns interrupts or cuts through the helical pattern of the smooth muscle at a proper pitch and prevents the airway from constricting. This procedure of patterned treatment application eliminates contraction of the airways without completely eradicating smooth muscle and other airway tissue. A pattern for treatment may be chosen from a variety of patterns including longitudinal or axial stripes, circumferential bands, helical stripes, and the like as well as spot patterns having rectangular, elliptical, circular or other shapes. The size, number, and spacing of the treatment bands, stripes, or spots are chosen to provide a desired clinical effect of reduced airway responsiveness while limiting insult to the airway to a clinically acceptable level.


The patterned treatment of the tissues surrounding the airways with energy provides various advantages. The careful selection of the portion of the airway to be treated allows desired results to be achieved while reducing the total healing load. Patterned treatment can also achieve desired results with decreased morbidity, preservation of epithelium, and preservation of a continuous or near continuous ciliated inner surface of the airway for mucociliary clearance. The pattern of treatment may also be chosen to achieve desired results while limiting total treatment area and/or the number of airways treated, thereby improving speed and ease of treatment.


Application of energy to the tissue surrounding the airways may also cause the DNA of the cells to become cross linked. The treated cells with cross linked DNA are incapable of replicating. Accordingly, over time, as the smooth muscle cells die, the total thickness of smooth muscle decreases because of the inability of the cells to replicate. The programmed cell death causing a reduction in the volume of tissue is called apoptosis. This treatment does not cause an immediate effect but causes shrinking of the smooth muscle and opening of the airway over time and substantially prevents re-growth. The application of energy to the walls of the airway may also be used to cause a cross linking of the DNA of the mucus gland cells thereby preventing them from replicating and reducing excess mucus plugging or production over time.


The ability of the airways to contract may also be reduced by altering mechanical properties of the airway wall, such as by increasing stiffness of the wall or by increasing parenchymal tethering of the airway wall. Both of these methods increase the strength of the airway wall and further oppose contraction and narrowing of the airway.


There are several ways to increase the stiffness of the airway wall. One way to increase stiffness is to induce fibrosis or a wound healing response by causing trauma to the airway wall. The trauma can be caused by delivery of therapeutic energy to the tissue in the airway wall, by mechanical insult to the tissue, or by chemically affecting the tissue. The energy is preferably delivered in such a way that it minimizes or limits the intra-luminal thickening that may occur.


Another way to increase the effective stiffness of the airway wall is to alter the submucosal folding of the airway upon narrowing. The mucosal layer includes the epithelium, its basement membrane, and the lamina propria, a subepithelial collagen layer. The submucosal layer may also play a role in airway folding. As an airway narrows, its perimeter remains relatively constant, with the mucosal layer folding upon itself. As the airway narrows further, the mucosal folds mechanically interfere with each other, effectively stiffening the airway. In asthmatic patients, the number of folds is fewer and the size of the folds is larger, and thus, the airway is free to narrow with less mechanical interference of mucosal folds than in a healthy patient. Thus, asthmatic patients have a decrease in airway stiffness and the airways have less resistance to narrowing.


The mucosal folding in asthmatic patients can be improved by treatment of the airway in a manner which encourages folding. Preferably, a treatment will increase the number of folds and/or decrease the size of the folds in the mucosal layer. For example, treatment of the airway wall in a pattern such as longitudinal stripes can encourage greater number of smaller mucosal folds and increase airway stiffness.


The mucosal folding can also be increased by encouraging a greater number of smaller folds by reducing the thickness of the mucosa and/or submucosal layer. The decreased thickness of the mucosa or submucosa may be achieved by application of energy which either reduces the number of cells in the mucosa or submucosal layer or which prevents replication of the cells in the mucosa or submucosal layer. A thinner mucosa or submucosal layer will have an increased tendency to fold and increased mechanical stiffening caused by the folds.


Another way to reduce the ability of the airways to contract is to improve parenchymal tethering. The parenchyma surrounds airways and includes the alveolus and tissue connected to and surrounding the outer portion of the airway wall. The parenchyma includes the alveolus and tissue connected to and surrounding the cartilage that supports the larger airways. In a healthy patient, the parenchyma provides a tissue network which connects to and helps to support the airway. Edema or accumulation of fluid in lung tissue in patients with asthma or COPD is believed to decouple the airway from the parenchyma reducing the restraining force of the parenchyma which opposes airway constriction. Energy can be used to treat the parenchyma to reduce edema and/or improve parenchymal tethering.


In addition, the applied energy may be used to improve connection between the airway smooth muscle and submucosal layer to the surrounding cartilage, and to encourage wound healing, collagen deposition, and/or fibrosis in the tissue surrounding the airway to help support the airway and prevent airway contraction.


Increasing the Airway Diameter


Hypertrophy of smooth muscle, chronic inflammation of airway tissues, and general thickening of all parts of the airway wall can reduce the airway diameter in patients with reversible obstructive pulmonary disease. Increasing the overall airway diameter using a variety of techniques can improve the passage of air through the airways. Application of energy to the airway smooth muscle of an asthmatic patient can debulk or reduce the volume of smooth muscle. This reduced volume of smooth muscle increases the airway diameter for improved air exchange.


Reducing inflammation and edema of the tissue surrounding the airway can also increase the diameter of an airway. Inflammation and edema (accumulation of fluid) of the airway are chronic features of asthma. The inflammation and edema can be reduced by application of energy to stimulate wound healing and regenerate normal tissue. Healing of the epithelium or sections of the epithelium experiencing ongoing denudation and renewal allows regeneration of healthy epithelium with less associated airway inflammation. The less inflamed airway has an increased airway diameter both at a resting state and in constriction. The wound healing can also deposit collagen which improves parenchymal tethering.


Inflammatory mediators released by tissue in the airway wall may serve as a stimulus for airway smooth muscle contraction. Therapy that reduces the production and release of inflammatory mediator can reduce smooth muscle contraction, inflammation of the airways, and edema. Examples of inflammatory mediators are cytokines, chemokines, and histamine. The tissues which produce and release inflammatory mediators include airway smooth muscle, epithelium, and mast cells. Treatment of these structures with energy can reduce the ability of the airway structures to produce or release inflammatory mediators. The reduction in released inflammatory mediators will reduce chronic inflammation, thereby increasing the airway inner diameter, and may also reduce hyper-responsiveness of the airway smooth muscle.


A further process for increasing the airway diameter is by denervation. A resting tone of smooth muscle is nerve regulated by release of catecholamines. Thus, by damaging or eliminating nerve tissue in the airways the resting tone of the smooth muscle is reduced, and the airway diameter is increased. Resting tone may also be reduced by directly affecting the ability of smooth muscle tissue to contract.


Reducing Plugging of the Airway


Excess mucus production and mucus plugging are common problems during both acute asthma exacerbation and in chronic asthma management. Excess mucus in the airways increases the resistance to airflow through the airways by physically blocking all or part of the airway. Excess mucus may also contribute to increased numbers of leukocytes found in airways of asthmatic patients by trapping leukocytes. Thus, excess mucus can increase chronic inflammation of the airways.


One type of asthma therapy involves treatment of the airways with energy to target and reduce the amount of mucus producing cells and glands and to reduce the effectiveness of the remaining mucus producing cells and glands. The treatment can eliminate all or a portion of the mucus producing cells and glands, can prevent the cells from replicating or can inhibit their ability to secrete mucus. This treatment will have both chronic benefits in increasing airflow through the airways and will lessen the severity of acute exacerbation of the symptoms of reversible obstructive pulmonary disease.


Illustrated below are different treatment devices for transferring energy into the airways. Described below are just some of the examples of the type of treatment devices which may be used to treat airway tissue according to the present disclosure. It should be recognized that each of the treatment devices described below can be modified to deliver or to remove energy in different patterns depending on the treatment to be performed. The treatment devices may be actuated continuously for a predetermined period while stationary, may be pulsed, may be actuated multiple times as they are moved along an airway, may be operated continuously while moving the device in an airway to achieve a “painting” of the airway, or may be actuated in a combination of any of these techniques. The particular energy application pattern desired can be achieved by configuring the treatment device itself or by moving the treatment device to different desired treatment locations in the airway.


Application of Treatment


The following illustrations are examples of the invention described herein. It is contemplated that combinations of aspects of specific embodiments or combinations of the specific embodiments themselves are within the scope of this disclosure.



FIGS. 1 and 2 illustrate cross sections of two different airways in a healthy patient. The airway of FIG. 1 is a medium sized bronchus having an airway diameter D1 of about 3 mm. FIG. 2 shows a section through a bronchiole having an airway diameter D2 of about 1.5 mm. Each airway includes a folded inner surface or epithelium 10 surrounded by stroma 12 and smooth muscle tissue 14. The larger airways including the bronchus shown in FIG. 1 also have mucous glands 16 and cartilage 18 surrounding the smooth muscle tissue 14. Nerve fibers 20 and blood vessels 24 also surround the airway.



FIG. 3 illustrates the bronchus of FIG. 1 in which the smooth muscle 14 has hypertrophied and increased in thickness causing the airway diameter to be reduced from the diameter D1 to a diameter D3.



FIG. 4 is a schematic side view of the lungs being treated with a treatment device 38 according to the present invention. The treatment device 38 is an elongated member for treating tissue at a treatment site 34 within a lung. Although the invention discusses treatment of tissue at the surface it is also intended that the invention include treatment below an epithelial layer of the lung tissue.


An example of devices for use with the methods of this invention are found in the following U.S. patent application Ser. No. 09/095,323—Methods and Apparatus for Treating Smooth Muscles in the Walls of Body Conduits; Ser. No. 09/349,715—Method of Increasing Gas Exchange of a Lung now U.S. Pat. No. 6,488,675; and Ser. No. 09/296,040—Devices for Modification of Airways By Transfer of Energy now U.S. Pat. No. 6,411,852; Ser. No. 09/436,455 Devices for Modification of Airways by Transfer of Energy. The entirety of each of the aforementioned applications is incorporated by reference herein.


The treatment of an airway with the treatment device may involve placing a visualization system such as an endoscope or bronchoscope into the airways. The treatment device is then inserted through or next to the bronchoscope or endoscope while visualizing the airways. Alternatively, the visualization system may be built directly into the treatment device using fiber optic imaging and lenses or a CCD and lens arranged at the distal portion of the treatment device. The treatment device may also be positioned using radiographic visualization such as fluoroscopy or other external visualization means. The treatment device which has been positioned with a distal end within an airway to be treated is energized so that energy is applied to the tissue of the airway walls in a desired pattern and intensity. The distal end of the treatment device may be moved through the airway in a uniform painting like motion to expose the entire length of an airway to be treated to the energy. The treatment device may be passed axially along the airway one or more times to achieve adequate treatment. The “painting-like” motion used to exposed the entire length of an airway to the energy may be performed by moving the entire treatment device from the proximal end either manually or by motor. Alternatively, segments, stripes, rings or other treatment patterns may be used.


According to one variation of the invention, the energy is transferred to or from an airway wall in the opening region of the airway, preferably within a length of approximately two times the airway diameter or less, and to wall regions of airways distal to bifurcations and side branches, preferably within a distance of approximately twice the airway diameter or less. The invention may also be used to treat long segments of un-bifurcated airway.


The invention includes a method of advancing a treatment device into a lung and treating the lung with the device to, at least, reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease. It is contemplated that the treatment may reduce all of the symptoms of reversible obstructive disease. Alternatively, the treatment may be selected to address specific symptoms of the disease. It is also intended that the treatment of the lung may sufficiently reduce the symptoms of reversible obstructive pulmonary disease such that the patient is able to function as those free from the disease. Alternatively, the treatment may be such that the symptoms are reduced to allow the patient to more easily manage the disease. It is also intended that the effects of the treatment may be either long term or short term with repeating treatment necessary to suppress the symptoms.


The methods of the invention described herein may be performed while the lung is experiencing natural symptoms of reversible obstructive pulmonary disease. One such example is where an individual, experiencing an asthma attack, or acute exacerbation of asthma or COPD, undergoes treatment to improve the individual's ability to breath. In such a case, the treatment, called ‘rescue,’ seeks to provide immediate relief for the patient.


The method may also include the steps of locating one or more treatment sites within an airway of the lung, selecting one of the treatment sites from the locating step and treating at least one of the selected treatment sites. As mentioned above, these steps may be, but are not necessarily, performed while the lung is experiencing symptoms of reversible obstructive pulmonary disease.


The invention may further comprise the step of stimulating the lung to produce at least one artificially induced symptom of reversible obstructive pulmonary disease. For example, stimulation of the lung would preferably increase the resistance to airflow within the lung, constrict airways within the lung, inflame/irritate airway tissues, increase edema and/or increase the amount of mucus plugging of the airway. Stimulation of the lung may occur at any point during the procedure or before the procedure. For example, the lung may be stimulated either prior to or after, the step of locating a treatment site. If the lung is stimulated prior to the step of locating a treatment site, the reaction of the stimulated tissue within the lung may be useful in determining which locations are to be selected as treatment sites. The lung tissue or airway tissue within the lung may be stimulated by a variety of methods including but not limited to pharmacological stimulation, (e.g., histamine, methacholine, or other bronchoconstricting agents, etc.), electrical stimulation, mechanical stimulation, or any other stimuli causing obstructive pulmonary symptoms. For example, electrical stimulation may comprise exposing airway tissue to electrical field stimulation. An example of such parameters include 15 VDC, 0.5 ms pulses, 0.5-16 Hz, and 70 VDC, 2-3 ms pulses, 20 HZ.


The locating step described above may be performed using a non-invasive imaging technique, including but not limited to, a bronchogram, magnetic resonance imaging, computed tomography, radiography (e.g., x-ray), and ventilation perfusion scans.


The invention further includes the steps of testing the lung for at least one pre-treatment pulmonary function value prior to treating the lung with the device. After the lung is treated, the lung is re-tested for at least one post-treatment pulmonary function value. Naturally, the two pulmonary function values may be compared to estimate the effect of the treatment. The invention may also include treating additional sites in the lung after the re-testing step to at least reduce the effect of at least one symptom of reversible obstructive pulmonary disease. The invention may also include stimulating the lung to produce at least one artificially induced symptom of reversible obstructive pulmonary disease. As mentioned above, the stimulation of the lung may occur at any point during, or prior to, the procedure. For example, stimulation of the lung may occur prior to the step of testing the lung for pre-treatment pulmonary values. In this case, the values would be determinative of pulmonary function values of a lung experiencing symptoms of reversible obstructive pulmonary disease. Accordingly, the objective is to treat the lung until acceptable pulmonary function values are obtained. One benefit of such a procedure is that the effect of the treatment on the patient is more readily observed as compared to the situation where a patient, having previously been treated, must wait for an attack of reversible obstructive pulmonary disease to determine the efficacy of the treatment.


Pulmonary function values are well known in the art. The following is an example of pulmonary function values that may be used. Other pulmonary function values, or combinations thereof, are intended to be within the scope of this invention. The values include, but are not limited to, FEV (forced expiratory volume), FVC (forced vital capacity), FEF (forced expiratory flow), Vmax (maximum flow), PEFR (peak expiratory flow rate), FRC (functional residual capacity), RV (residual volume), TLC (total lung capacity).


FEV measures the volume of air exhaled over a pre-determined period of time by a forced expiration immediately after a full inspiration. FVC measures the total volume of air exhaled immediately after a full inspiration. Forced expiratory flow measures the volume of air exhaled during a FVC divided by the time in seconds. Vmax is the maximum flow measured during FVC. PEFR measures the maximum flow rate during a forced exhale starting from full inspiration. RV is the volume of air remaining in the lungs after a full expiration.


The locating step described above may also comprise identifying treatment sites within the airway being susceptible to a symptom of reversible obstructive pulmonary disease. For example, symptoms may include, but are not limited to, airway inflammation, airway constriction, excessive mucous secretion, or any other asthmatic symptom. Stimulation of the lung to produce symptoms of reversible obstructive pulmonary disease may assist in identifying ideal treatment sites.


As noted above, the method of the present invention may include stimulating the lung to produce at least one artificially induced symptom of reversible obstructive pulmonary disease and further include the step of evaluating the result of stimulation of the lung. For example, the evaluating step may include visually evaluating the effect of the stimulating step on the airway using a bronchoscope with a visualization system or by non-invasive imaging techniques, such as those describe herein. The evaluating step may include measuring pressure changes in the airway before and after the stimulating step. Pressure may be measured globally (e.g., within the entire lung), or locally (e.g., within a specific section of the lung such as an airway or alveolar sac.) Also, the evaluating step may comprise measuring the electrical properties of the tissue before and after the stimulating step. The invention may also include evaluating the results of the stimulating step by combining any of the methods previously mentioned. Also, the invention may further comprise the step of selecting at least one treatment parameter based upon the results of the evaluating step. Such treatment parameters may include, but are not limited to, duration of treatment, intensity of treatment, temperature, amount of tissue treated, depth of treatment, etc.


The method may also include the step of determining the effect of the treatment by visually observing lung, airway or other such tissue for blanching of the tissue. The term “blanching” is intended to include any physical change in tissue that is usually, but not necessarily, accompanied by a change in the color of the tissue. One example of such blanching is where the tissue turns to a whitish color after the treatment of application of energy.


The invention may also include the step of monitoring impedance across a treated area of tissue within the lung. Measuring impedance may be performed in cases of monopolar or bipolar energy delivery devices. Additionally, impedance may be monitored at more than one site within the lungs. The measuring of impedance may be, but is not necessarily, performed by the same electrodes used to deliver the energy treatment to the tissue. Furthermore, the invention includes adjusting the treatment parameters based upon the monitoring of the change in impedance after the treatment step. For example, as the energy treatment affects the properties of the treated tissue, measuring changes in impedance may provide information useful in adjusting treatment parameters to obtain a desired result.


Another aspect of the invention includes advancing a treatment device into the lung and treating lung tissue to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease and further comprising the step of sub-mucosal sensing of the treatment to the lung tissue. The sub-mucosal sensing may be invasive such as when using a probe equipped to monitor temperature, impedance, and/or blood flow. Or, the sub-mucosal sensing may be non-invasive in such cases as infra-red sensing.


The invention may also include using the treatment device to deposit radioactive substances at select treatment sites within the lung. The radioactive substances, including, but not limited to Iridium (e.g. 192Ir.) either treat the lung tissue over time or provide treatment upon being deposited.


The invention also includes scraping epithelial tissue from the wall of an airway within the lung prior to advancing a treatment device into the lung to treat the lung tissue. The removal of the epithelial tissue allows the device to treat the walls of an airway more effectively. The invention further comprises the step of depositing a substance on the scraped wall of the airway after the device treats the airway wall. The substance may include epithelial tissue, collagen, growth factors, or any other bio-compatible tissue or substance, which promotes healing, prevent infection, and/or assists in the clearing of mucus. Alternatively, the treatment may comprise the act of scraping epithelial tissue to induce yield the desired response.


The invention includes using the treating device to pre-treat the lung to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease prior to the treating step. At least one of the parameters of the pre-treating step may differ than one of the parameters of the treating step. Such parameters may include time, temperature, amount of tissue over which treatment is applied, amount of energy applied, depth of treatment, etc.


The invention may also include advancing the treatment device into the lung and treating the lung tissue in separate stages. One of the benefits of dividing the treating step into separate stages is that the healing load of the patient is lessened. Dividing of the treating step may be accomplished by treating different regions of the lung at different times. Or, the total number of treatment sites may be divided into a plurality of groups of treatment sites, where each group of treatment sites is treated at a different time. The amount of time between treatments may be chosen such that the healing load placed on the lungs is minimized.


The invention may also include advancing a treatment device into the lung, treating the lung with the device and sensing movement of the lung to reposition the treatment device in response to the movement. This sensing step accounts for the tidal motion of the lung during breathing cycles or other movement. Taking into account the tidal motion allows improved accuracy in repositioning of the device at a desired target.


The invention may also include the additional step of reducing or stabilizing the temperature of lung tissue near to a treatment site. This may be accomplished for example, by injecting a cold fluid into lung parenchyma or into the airway being treated, where the airway is proximal, distal, or circumferentially adjacent to the treatment site. The fluid may be sterile normal saline, or any other bio-compatible fluid. The fluid may be injected into treatment regions within the lung while other regions of the lung normally ventilated by gas. Or, the fluid may be oxygenated to eliminate the need for alternate ventilation of the lung. Upon achieving the desired reduction or stabilization of temperature the fluid may be removed from the lungs. In the case where a gas is used to reduce temperature, the gas may be removed from the lung or allowed to be naturally exhaled. One benefit of reducing or stabilizing the temperature of the lung may be to prevent excessive destruction of the tissue, or to prevent destruction of certain types of tissue such as the epithelium, or to reduce the systemic healing load upon the patient's lung.


Also contemplated as within the scope of the invention is the additional step of providing therapy to further reduce the effects of reversible obstructive pulmonary disease or which aids the healing process after such treatment. Some examples of therapy include, drug therapy, exercise therapy, and respiratory therapy. The invention further includes providing education on reversible obstructive pulmonary disease management techniques to further reduce the effects of the disease. For example, such techniques may be instruction on lifestyle changes, self-monitoring techniques to assess the state of the disease, and/or medication compliance education.


There may be occurrences where it is necessary to reverse the effects of the treatment described herein. Accordingly, the invention further includes a method for reversing a treatment to reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease comprising the step of stimulating re-growth of smooth muscle tissue. The re-stimulation of the muscle may be accomplished by the use of electro-stimulation, exercising of the muscle and/or drug therapy.


The invention further includes methods of evaluating individuals having reversible obstructive pulmonary disease, or a symptom thereof, as a candidate for a procedure to reduce the ability of the individual's lung to produce at least one symptom of reversible obstructive pulmonary disease. The method comprises the steps of assessing the pulmonary condition of the individual, comparing the pulmonary condition to a corresponding pre-determined state, and evaluate the individual as a candidate based upon the comparison.


In assessing the pulmonary condition, the method may comprise the steps of performing pulmonary function tests on the individual to obtain a pulmonary function value which is compared to a predetermined value. Examples of pre-determined values are found above.


The method of evaluating may further include the step of determining how the individual's tissue will react to treatment allowing the treatment to be tailored to the expected tissue response.


The method of evaluating may further comprises the step of pulmonary function testing using a gas, a mixture of gases, or a composition of several mixtures of gases to ventilate the lung. The difference in properties of the gases may aid in the pulmonary function testing. For example, comparison of one or more pulmonary function test values that are obtained with the patient breathing gas mixtures of varying densities may help to diagnose lung function. Examples of such mixtures include air, at standard atmospheric conditions, and a mixture of helium and oxygen. Additional examples of pulmonary testing include tests that measure capability and evenness of ventilation given diffusion of special gas mixtures. Other examples of gases used in the described tests, include but are not limited to, nitrogen, carbon monoxide, carbon dioxide, and a range of inert gases.


The invention may also comprise the step of stimulating the lung to produce at least one artificially induced symptom of reversible obstructive pulmonary disease. Stimulating the symptoms of the disease in an individual allows the individual to be evaluated as the individual experiences the symptoms thereby allowing appropriate adjustment of the treatment.


The method of evaluating may also comprise the step of obtaining clinical information from the individual and accounting for the clinical information for treatment.


The method may further comprise the selection of a patient for treatment based upon a classification of the subtype of the patient's disease. For example, in asthma there are a number of ways to classify the disease state. One such method is the assessment of the severity of the disease. An example of a classification scheme by severity is found in the NHLBI Expert Panel 2 Guidelines for the Diagnosis and Treatment of Asthma. Another selection method may include selecting a patient by the type of trigger that induces the exacerbation. Such triggers may be classified further by comparing allergic versus non-allergic triggers. For instance, an exercise induced bronchospasm (EIB) is an example of a non-allergenic trigger. The allergic sub-type may be further classified according to specific triggers (e.g., dust mites, animal dander, etc.). Another classification of the allergic sub-type may be according to characteristic features of the immune system response such as levels of IgE (a class of antibodies that function in allergic reactions, also called immunoglobulin). Yet another classification of allergic sub-types may be according to the expression of genes controlling certain interleukins (e.g., IL-4, IL-5, etc.) which have been shown to play a key role in certain types of asthma.


The invention further comprises methods to determine the completion of the procedure and the effectiveness of the reduction in the lung's ability to produce at least one symptom of reversible obstructive pulmonary disease. This variation of the invention comprises assessing the pulmonary condition of the individual, comparing the pulmonary condition to a corresponding predetermined state, and evaluating the effectiveness of the procedure based on the comparison. The invention may also comprise the steps of performing pulmonary function tests on the individual to obtain at least one pulmonary function value, treating the lung to at least reduce the ability of the lung to produce at least one symptom of reversible obstructive pulmonary disease, performing a post-procedure pulmonary function tests on the individual to obtain at least one post pulmonary function value and comparing the two values.


This variation of the invention comprises obtaining clinical information, evaluating the clinical information with the results of the test to determine the effectiveness of the procedure. Furthermore, the variation may include stimulating the lung to produce a symptom of reversible obstructive pulmonary disease, assessing the pulmonary condition of the patient, then repeating the stimulation before the post-procedure pulmonary therapy. These steps allow comparison of the lung function when it is experiencing symptoms of reversible obstructive pulmonary disease, before and after the treatment, thereby allowing for an assessment of the improved efficiency of the lung during an attack of the disease.


A power supply may also include circuitry for monitoring parameters of energy transfer: (for example, voltage, current, power, impedance, as well as temperature from the temperature sensing element), and use this information to control the amount of energy delivered.


A power supply may also include control modes for delivering energy safely and effectively. Energy may be delivered in open loop power control mode for a specific time duration. Energy may also be delivered in temperature control mode, with output power varied to maintain a certain temperature for a specific time duration. In the case of RF energy delivery via RF electrodes, the power supply may operate in impedance control mode.


In temperature control mode with RF electrodes described here, the power supply will operate at up to a 75° C. setting. The duration must be long enough to produce the desired effect, but as short as possible to allow treatment of all of the desired target airways within a lung. For example, 5 to 10 seconds per activation (while the device is stationary) is preferred. Shorter duration with higher temperature will also produce acceptable acute effect.


Using RF electrodes as described above in power control mode, power ranges of 10-15 W with durations of 3-5 seconds are preferred but may be varied. It should be noted that different device constructions utilize different parameter settings to achieve the desired effect. For example, while direct RF electrodes typically utilize temperatures up to 75° C. in temperature control mode, the resistively heated electrodes may utilize temperatures up to 90° C. Also, in addition to the control modes specified above, the power supply may include control algorithms to limit excessive thermal damage to the airway tissue. For example, in order to stop delivery of energy in the event of contact between airway tissue and device legs having temperature sensing capabilities, an algorithm may be employed to shut down energy delivery if the sensed temperature does not rise by a certain number of degrees in a pre-specified amount of time after energy delivery begins. Another way to stop energy delivery includes shutting down a power supply if the temperature ramp is not within a predefined range at any time during energy delivery. Other algorithms include shutting down a power supply if a maximum temperature setting is exceeded or shutting down a power supply if the sensed temperature suddenly changes, such a change includes either a drop or rise, this change may indicate failure of the temperature sensing element.


The invention herein is described by examples and a desired way of practicing the invention is described. However, the invention as claimed herein is not limited to that specific description in any manner. Equivalence to the description as hereinafter claimed is considered to be within the scope of protection of this patent.

Claims
  • 1. A method for reducing inflammation of airway tissue in a lung, the method comprising: positioning an energy transfer device in an airway of the lung, the airway having a wall; andactuating the energy transfer device multiple times as the energy transfer device is moved along the airway to transfer energy along the length of the airway wall at a plurality of treatment sites to form a repeating pattern of treated segments extending along the length of the airway wall that reduces an inflammatory response of the airway tissue, wherein actuating the energy transfer device is performed in a plurality of airways in different regions of the lung at different times such that an amount of time between treating the different regions of the lung lessens a healing load placed on the lung.
  • 2. The method of claim 1, wherein the transfer of energy comprises delivering RF energy to the treatment sites at up to 75° C. for 5-10 seconds.
  • 3. The method of claim 1, where the transfer of energy disrupts the inflammatory response by altering production or release of inflammatory mediators in at least a part of the airway.
  • 4. The method of claim 1, where the transfer of energy disrupts the inflammatory response by preventing replication of structures producing or releasing inflammatory mediators.
  • 5. The method of claim 1, where the transfer of energy disrupts the inflammatory response by eliminating at least a portion of the structures which produce or release inflammatory mediators.
  • 6. The method of claim 5, where the transfer of energy disrupts the inflammatory response by altering the ability of structures in the airway to produce or release inflammatory mediators.
  • 7. The method of claim 1, where the energy is selected from a modality selected from the group consisting of chemical, radio frequency, radioactive energy, heat, and ultrasound.
  • 8. The method of claim 1, wherein the actuating the energy transfer device multiple times is repeated along the entire length of the airway wall.
  • 9. The method of claim 1, wherein: the energy transfer device includes an expandable basket having a plurality of electrodes configured to concurrently contact a plurality of points circumferentially around the airway wall;the energy transfer device is moved along the airway by collapsing the electrodes and repositioning the energy transfer device along the airway; andthe energy is transferred to the plurality of treatment sites by expanding the electrodes at each treatment site such that the electrodes contact the airway wall.
  • 10. The method of claim 9, where the repeating pattern of treated segments includes one or more spots having a rectangular, elliptical, circular, or other shape.
  • 11. The method of claim 9, where at least one of the treated segments extends longitudinally along the airway wall.
  • 12. The method of claim 9, where the repeating pattern of treated segments is of at least one stripe extending along the airway in a longitudinal or helical pattern.
Parent Case Info

This is a continuation of U.S. application Ser. No. 10/640,967, filed Aug. 13, 2003, now U.S. Pat. No. 7,273,055, which is a continuation of U.S. application Ser. No. 09/535,856, filed Mar. 27, 2000, now U.S. Pat. No. 6,634,363, which is a continuation-in-part application of U.S. application Ser. No. 09/296,040, filed Apr. 21, 1999, now U.S. Pat. No. 6,411,852, which is a continuation-in-part of U.S. application Ser. No. 09/095,323, filed Jun. 10, 1998 now abandoned; this is also a continuation-in-part application of U.S. application Ser. No. 09/436,455, filed Nov. 8, 1999, now U.S. Pat. No. 7,425,212, which is a continuation-in-part of U.S. application Ser. No. 09/095,323, filed Jun. 10, 1998 now abandoned, and is also a continuation-in-part of U.S. application Ser. No. 09/349,715, filed Jul. 8, 1999, now U.S. Pat. No. 6,488,673. All the above applications are incorporated by reference herein in their entirety.

US Referenced Citations (520)
Number Name Date Kind
612724 Hamilton Oct 1898 A
1155169 Starkweather Sep 1915 A
1207479 Bisgaard Dec 1916 A
1216183 Swingle Feb 1917 A
2072346 Smith Mar 1937 A
3320957 Sokolik May 1967 A
3568659 Karnegis Mar 1971 A
3667476 Muller Jun 1972 A
3692029 Adair Sep 1972 A
3995617 Watkins et al. Dec 1976 A
4095602 Leveen Jun 1978 A
4116589 Rishton Sep 1978 A
4129129 Amrine Dec 1978 A
4154246 LeVeen May 1979 A
4461283 Doi Jul 1984 A
4502490 Evans et al. Mar 1985 A
4503855 Maslanka Mar 1985 A
4512762 Spears Apr 1985 A
4522212 Gelinas et al. Jun 1985 A
4557272 Carr Dec 1985 A
4565200 Cosman Jan 1986 A
4567882 Heller Feb 1986 A
4584998 McGrail Apr 1986 A
4612934 Borkan Sep 1986 A
4621642 Chen Nov 1986 A
4621882 Krumme Nov 1986 A
4625712 Wampler Dec 1986 A
4643186 Rosen et al. Feb 1987 A
4646737 Hussein et al. Mar 1987 A
4674497 Ogasawara Jun 1987 A
4683890 Hewson Aug 1987 A
4704121 Moise Nov 1987 A
4706688 Don Michael et al. Nov 1987 A
4709698 Johnston et al. Dec 1987 A
4739759 Rexroth et al. Apr 1988 A
4754065 Levenson et al. Jun 1988 A
4754752 Ginsburg et al. Jul 1988 A
4765959 Fukasawa Aug 1988 A
4772112 Zider et al. Sep 1988 A
4773899 Spears Sep 1988 A
4779614 Moise Oct 1988 A
4784135 Blum et al. Nov 1988 A
4790305 Zoltan et al. Dec 1988 A
4799479 Spears Jan 1989 A
4802492 Grunstein Feb 1989 A
4817586 Wampler Apr 1989 A
4825871 Cansell May 1989 A
4827935 Geddes et al. May 1989 A
4846152 Wampler et al. Jul 1989 A
4862886 Clarke et al. Sep 1989 A
4895557 Moise et al. Jan 1990 A
4906229 Wampler Mar 1990 A
4907589 Cosman Mar 1990 A
4908012 Moise et al. Mar 1990 A
4920978 Colvin May 1990 A
4944722 Carriker et al. Jul 1990 A
4955377 Lennox et al. Sep 1990 A
4967765 Turner et al. Nov 1990 A
4969865 Hwang et al. Nov 1990 A
4976709 Sand Dec 1990 A
4985014 Orejola Jan 1991 A
4991603 Cohen et al. Feb 1991 A
5009636 Wortley et al. Apr 1991 A
5009936 Yamanaka et al. Apr 1991 A
5010892 Colvin et al. Apr 1991 A
5019075 Spears et al. May 1991 A
5027829 Larsen Jul 1991 A
5030645 Kollonitsch Jul 1991 A
5036848 Hewson Aug 1991 A
5053033 Clarke Oct 1991 A
5056519 Vince Oct 1991 A
5074860 Gregory et al. Dec 1991 A
5078716 Doll Jan 1992 A
5084044 Quint Jan 1992 A
5096916 Skupin Mar 1992 A
5100388 Behl et al. Mar 1992 A
5100423 Fearnot Mar 1992 A
5103804 Abele et al. Apr 1992 A
5105826 Smits et al. Apr 1992 A
5106360 Ishiwara et al. Apr 1992 A
5107830 Younes Apr 1992 A
5114423 Kasprzyk et al. May 1992 A
5116864 March et al. May 1992 A
5117828 Metzger et al. Jun 1992 A
5135517 McCoy Aug 1992 A
5152286 Sitko et al. Oct 1992 A
5165420 Strickland Nov 1992 A
5167223 Koros et al. Dec 1992 A
5170803 Hewson et al. Dec 1992 A
5174288 Bardy et al. Dec 1992 A
5188602 Nichols Feb 1993 A
5191883 Lennox et al. Mar 1993 A
5213576 Abiuso et al. May 1993 A
5215103 Desai Jun 1993 A
5231996 Bardy et al. Aug 1993 A
5232444 Just et al. Aug 1993 A
5234456 Silvestrini Aug 1993 A
5254088 Lundquist et al. Oct 1993 A
5255678 Deslauriers et al. Oct 1993 A
5255679 Imran Oct 1993 A
5265604 Vince Nov 1993 A
5269758 Taheri Dec 1993 A
5281218 Imran Jan 1994 A
5292331 Boneau Mar 1994 A
5293869 Edwards et al. Mar 1994 A
5309910 Edwards et al. May 1994 A
5313943 Houser et al. May 1994 A
5324284 Imran Jun 1994 A
5343936 Beatenbough et al. Sep 1994 A
5345936 Pomeranz et al. Sep 1994 A
5366443 Eggers et al. Nov 1994 A
5368591 Lennox et al. Nov 1994 A
5370644 Langberg Dec 1994 A
5370679 Atlee, III Dec 1994 A
5374287 Rubin Dec 1994 A
5383917 Desai et al. Jan 1995 A
5393207 Maher et al. Feb 1995 A
5394880 Atlee, III Mar 1995 A
5396887 Imran Mar 1995 A
5400778 Jonson et al. Mar 1995 A
5400783 Pomeranz et al. Mar 1995 A
5411025 Webster, Jr. May 1995 A
5415166 Imran May 1995 A
5415656 Tihon et al. May 1995 A
5417687 Nardella et al. May 1995 A
5422362 Vincent et al. Jun 1995 A
5423744 Gencheff et al. Jun 1995 A
5423811 Imran et al. Jun 1995 A
5425023 Haraguchi et al. Jun 1995 A
5425703 Feiring Jun 1995 A
5425811 Mashita Jun 1995 A
5431696 Atlee, III Jul 1995 A
5433730 Alt Jul 1995 A
5437665 Munro Aug 1995 A
5443470 Stern et al. Aug 1995 A
5454782 Perkins Oct 1995 A
5456667 Ham et al. Oct 1995 A
5458596 Lax et al. Oct 1995 A
5465717 Imran et al. Nov 1995 A
5471982 Edwards et al. Dec 1995 A
5474530 Passafaro et al. Dec 1995 A
5478309 Sweezer et al. Dec 1995 A
5496271 Burton et al. Mar 1996 A
5496311 Abele et al. Mar 1996 A
5496312 Klicek Mar 1996 A
5500011 Desai Mar 1996 A
5505728 Ellman et al. Apr 1996 A
5505730 Edwards Apr 1996 A
5507791 Sit'ko Apr 1996 A
5509419 Edwards et al. Apr 1996 A
5522862 Testerman et al. Jun 1996 A
5531779 Dahl et al. Jul 1996 A
5540681 Strul et al. Jul 1996 A
5545161 Imran Aug 1996 A
5545193 Fleischman et al. Aug 1996 A
5547469 Rowland et al. Aug 1996 A
5549559 Eshel Aug 1996 A
5549655 Erickson Aug 1996 A
5549661 Kordis et al. Aug 1996 A
RE35330 Malone et al. Sep 1996 E
5558073 Pomeranz et al. Sep 1996 A
5562608 Sekins et al. Oct 1996 A
5571074 Buckman, Jr. et al. Nov 1996 A
5571088 Lennox et al. Nov 1996 A
5574059 Regunathan et al. Nov 1996 A
5578072 Barone et al. Nov 1996 A
5582609 Swanson et al. Dec 1996 A
5588432 Crowley Dec 1996 A
5588812 Taylor et al. Dec 1996 A
5595183 Swanson et al. Jan 1997 A
5598848 Swanson et al. Feb 1997 A
5599345 Edwards et al. Feb 1997 A
5601088 Swanson et al. Feb 1997 A
5605157 Panescu et al. Feb 1997 A
5607419 Amplatz et al. Mar 1997 A
5607462 Imran Mar 1997 A
5620438 Amplatz et al. Apr 1997 A
5623940 Daikuzono Apr 1997 A
5624439 Edwards et al. Apr 1997 A
5626618 Ward et al. May 1997 A
5630425 Panescu et al. May 1997 A
5630794 Lax et al. May 1997 A
5634471 Fairfax et al. Jun 1997 A
5641326 Adams Jun 1997 A
5647870 Kordis et al. Jul 1997 A
5660175 Dayal Aug 1997 A
5678535 DiMarco Oct 1997 A
5680860 Imran Oct 1997 A
5681280 Rusk et al. Oct 1997 A
5681308 Edwards et al. Oct 1997 A
5687723 Avitall Nov 1997 A
5688267 Panescu et al. Nov 1997 A
5693078 Desai et al. Dec 1997 A
5694934 Edelman Dec 1997 A
5695471 Wampler Dec 1997 A
5699799 Xu et al. Dec 1997 A
5702386 Stern et al. Dec 1997 A
5707218 Maher et al. Jan 1998 A
5707336 Rubin Jan 1998 A
5707352 Sekins et al. Jan 1998 A
5722401 Pietroski et al. Mar 1998 A
5722403 McGee et al. Mar 1998 A
5722416 Swanson et al. Mar 1998 A
5725525 Kordis Mar 1998 A
5727569 Benetti et al. Mar 1998 A
5728094 Edwards Mar 1998 A
5730128 Pomeranz et al. Mar 1998 A
5730704 Avitall Mar 1998 A
5730726 Klingenstein Mar 1998 A
5730741 Horzewski et al. Mar 1998 A
5735846 Panescu et al. Apr 1998 A
5740808 Panescu et al. Apr 1998 A
5741248 Stern et al. Apr 1998 A
5752518 McGee et al. May 1998 A
5755714 Murphy-Chutorian May 1998 A
5755753 Knowlton May 1998 A
5759158 Swanson Jun 1998 A
5765568 Sweezer, Jr. et al. Jun 1998 A
5769846 Edwards et al. Jun 1998 A
5772590 Webster, Jr. Jun 1998 A
5779669 Haissaguerre et al. Jul 1998 A
5779698 Clayman et al. Jul 1998 A
5782239 Webster, Jr. Jul 1998 A
5782797 Schweich, Jr. et al. Jul 1998 A
5782827 Gough et al. Jul 1998 A
5782848 Lennox Jul 1998 A
5782899 Imran Jul 1998 A
5792064 Panescu et al. Aug 1998 A
5795303 Swanson et al. Aug 1998 A
5800375 Sweezer et al. Sep 1998 A
5807306 Shapland et al. Sep 1998 A
5810757 Sweezer, Jr. et al. Sep 1998 A
5810807 Ganz et al. Sep 1998 A
5817028 Anderson Oct 1998 A
5817073 Krespi Oct 1998 A
5820554 Davis et al. Oct 1998 A
5823189 Kordis Oct 1998 A
5827277 Edwards Oct 1998 A
5833651 Donovan et al. Nov 1998 A
5836905 Lemelson et al. Nov 1998 A
5836947 Fleischman et al. Nov 1998 A
5837001 Mackey Nov 1998 A
5843075 Taylor Dec 1998 A
5843077 Edwards Dec 1998 A
5846238 Jackson et al. Dec 1998 A
5848969 Panescu et al. Dec 1998 A
5848972 Triedman et al. Dec 1998 A
5849026 Zhou et al. Dec 1998 A
5855577 Murphy-Chutorian et al. Jan 1999 A
5860974 Abele Jan 1999 A
5863291 Schaer Jan 1999 A
5865791 Whayne et al. Feb 1999 A
5868740 LeVeen et al. Feb 1999 A
5871443 Edwards et al. Feb 1999 A
5871523 Fleischman et al. Feb 1999 A
5873852 Vigil et al. Feb 1999 A
5873865 Horzewski et al. Feb 1999 A
5876340 Tu et al. Mar 1999 A
5876399 Chia et al. Mar 1999 A
5881727 Edwards Mar 1999 A
5882346 Pomeranz et al. Mar 1999 A
5891135 Jackson et al. Apr 1999 A
5891136 McGee et al. Apr 1999 A
5891138 Tu et al. Apr 1999 A
5893847 Kordis Apr 1999 A
5897554 Chia et al. Apr 1999 A
5899882 Waksman et al. May 1999 A
5904651 Swanson et al. May 1999 A
5904711 Flom et al. May 1999 A
5906636 Casscells et al. May 1999 A
5908445 Whayne et al. Jun 1999 A
5908446 Imran Jun 1999 A
5908839 Levitt et al. Jun 1999 A
5911218 DiMarco Jun 1999 A
5916235 Guglielmi Jun 1999 A
5919147 Jain Jul 1999 A
5919172 Golba, Jr. Jul 1999 A
5924424 Stevens et al. Jul 1999 A
5928228 Kordis et al. Jul 1999 A
5931835 Mackey Aug 1999 A
5935079 Swanson et al. Aug 1999 A
5941869 Patterson et al. Aug 1999 A
5951494 Wang et al. Sep 1999 A
5951546 Lorentzen Sep 1999 A
5954661 Greenspon et al. Sep 1999 A
5954662 Swanson et al. Sep 1999 A
5954717 Behl et al. Sep 1999 A
5957961 Maguire et al. Sep 1999 A
5964753 Edwards Oct 1999 A
5964796 Imran Oct 1999 A
5971983 Lesh Oct 1999 A
5972026 Laufer et al. Oct 1999 A
5976175 Hirano et al. Nov 1999 A
5976709 Kageyama et al. Nov 1999 A
5979456 MaGovern Nov 1999 A
5980563 Tu et al. Nov 1999 A
5984917 Fleischman et al. Nov 1999 A
5984971 Faccioli et al. Nov 1999 A
5991650 Swanson et al. Nov 1999 A
5992419 Sterzer et al. Nov 1999 A
5993462 Pomeranz et al. Nov 1999 A
5997534 Tu et al. Dec 1999 A
5999855 DiMarco Dec 1999 A
6001054 Regulla et al. Dec 1999 A
6003517 Sheffield et al. Dec 1999 A
6004269 Crowley et al. Dec 1999 A
6006755 Edwards Dec 1999 A
6008211 Robinson et al. Dec 1999 A
6009877 Edwards Jan 2000 A
6010500 Sherman et al. Jan 2000 A
6014579 Pomeranz et al. Jan 2000 A
6016437 Tu et al. Jan 2000 A
6023638 Swanson Feb 2000 A
6024740 Lesh et al. Feb 2000 A
6029091 De La Rama et al. Feb 2000 A
6033397 Laufer et al. Mar 2000 A
6036687 Laufer et al. Mar 2000 A
6036689 Tu et al. Mar 2000 A
6039731 Taylor et al. Mar 2000 A
6045549 Smethers et al. Apr 2000 A
6045550 Simpson et al. Apr 2000 A
6050992 Nichols Apr 2000 A
6053172 Hovda et al. Apr 2000 A
6053909 Shadduck Apr 2000 A
6056744 Edwards May 2000 A
6056769 Epstein et al. May 2000 A
6063078 Wittkampf May 2000 A
6071280 Edwards et al. Jun 2000 A
6071281 Burnside et al. Jun 2000 A
6071282 Fleischman Jun 2000 A
6083255 Laufer et al. Jul 2000 A
6090104 Webster, Jr. Jul 2000 A
6092528 Edwards Jul 2000 A
6102886 Lundquist et al. Aug 2000 A
6106524 Eggers et al. Aug 2000 A
6123702 Swanson et al. Sep 2000 A
6123703 Tu et al. Sep 2000 A
6139527 Laufer et al. Oct 2000 A
6139571 Fuller et al. Oct 2000 A
6142993 Whayne et al. Nov 2000 A
6143013 Samson et al. Nov 2000 A
6149647 Tu et al. Nov 2000 A
6152143 Edwards Nov 2000 A
6152899 Farley et al. Nov 2000 A
6159194 Eggers et al. Dec 2000 A
6179833 Taylor Jan 2001 B1
6183468 Swanson et al. Feb 2001 B1
6198970 Freed et al. Mar 2001 B1
6200311 Danek et al. Mar 2001 B1
6200332 Del Giglio Mar 2001 B1
6200333 Laufer Mar 2001 B1
6210367 Carr Apr 2001 B1
6212433 Behl Apr 2001 B1
6214002 Fleischman et al. Apr 2001 B1
6216043 Swanson et al. Apr 2001 B1
6216044 Kordis Apr 2001 B1
6217576 Tu et al. Apr 2001 B1
6235024 Tu May 2001 B1
6241727 Tu et al. Jun 2001 B1
6245065 Panescu et al. Jun 2001 B1
6254598 Edwards et al. Jul 2001 B1
6258087 Edwards et al. Jul 2001 B1
6264653 Falwell Jul 2001 B1
6269813 Fitzgerald et al. Aug 2001 B1
6270476 Santoianni et al. Aug 2001 B1
6273907 Laufer Aug 2001 B1
6283988 Laufer et al. Sep 2001 B1
6283989 Laufer et al. Sep 2001 B1
6287304 Eggers et al. Sep 2001 B1
6296639 Truckai et al. Oct 2001 B1
6299633 Laufer Oct 2001 B1
6322559 Daulton et al. Nov 2001 B1
6322584 Ingle et al. Nov 2001 B2
6338727 Noda et al. Jan 2002 B1
6338836 Kuth et al. Jan 2002 B1
6346104 Daly et al. Feb 2002 B2
6355031 Edwards et al. Mar 2002 B1
6379352 Reynolds et al. Apr 2002 B1
6409723 Edwards Jun 2002 B1
6411852 Danek et al. Jun 2002 B1
6416511 Lesh et al. Jul 2002 B1
6416740 Unger Jul 2002 B1
6423105 Iijima et al. Jul 2002 B1
6425895 Swanson et al. Jul 2002 B1
6440129 Simpson Aug 2002 B1
6442435 King et al. Aug 2002 B2
6458121 Rosenstock et al. Oct 2002 B1
6460545 Kordis Oct 2002 B2
6488673 Laufer et al. Dec 2002 B1
6488679 Swanson et al. Dec 2002 B1
6493589 Medhkour et al. Dec 2002 B1
6494880 Swanson et al. Dec 2002 B1
6496738 Carr Dec 2002 B2
6514246 Swanson et al. Feb 2003 B1
6526320 Mitchell Feb 2003 B2
6529756 Phan et al. Mar 2003 B1
6544226 Gaiser et al. Apr 2003 B1
6544262 Fleischman Apr 2003 B2
6547788 Maguire et al. Apr 2003 B1
6558378 Sherman et al. May 2003 B2
6572612 Stewart et al. Jun 2003 B2
6575623 Werneth Jun 2003 B2
6575969 Rittman, III et al. Jun 2003 B1
6582427 Goble et al. Jun 2003 B1
6582430 Hall Jun 2003 B2
6589235 Wong et al. Jul 2003 B2
6610054 Edwards et al. Aug 2003 B1
6620159 Hegde Sep 2003 B2
6626903 McGuckin, Jr. et al. Sep 2003 B2
6634363 Danek et al. Oct 2003 B1
6635056 Kadhiresan et al. Oct 2003 B2
6638273 Farley et al. Oct 2003 B1
6640120 Swanson et al. Oct 2003 B1
6645200 Koblish et al. Nov 2003 B1
6652548 Evans et al. Nov 2003 B2
6669693 Friedman Dec 2003 B2
6673068 Berube Jan 2004 B1
6692492 Simpson et al. Feb 2004 B2
6699243 West et al. Mar 2004 B2
6714822 King et al. Mar 2004 B2
6723091 Goble et al. Apr 2004 B2
6743197 Edwards Jun 2004 B1
6749604 Eggers et al. Jun 2004 B1
6749606 Keast et al. Jun 2004 B2
6767347 Sharkey et al. Jul 2004 B2
6770070 Balbierz Aug 2004 B1
6802843 Truckai et al. Oct 2004 B2
6805131 Kordis Oct 2004 B2
6837888 Ciarrocca et al. Jan 2005 B2
6840243 Deem et al. Jan 2005 B2
6849073 Hoey et al. Feb 2005 B2
6852091 Edwards et al. Feb 2005 B2
6852110 Roy et al. Feb 2005 B2
6866662 Fuimaono et al. Mar 2005 B2
6881213 Ryan et al. Apr 2005 B2
6893436 Woodard et al. May 2005 B2
6893439 Fleischman May 2005 B2
6895267 Panescu et al. May 2005 B2
6904303 Phan et al. Jun 2005 B2
6917834 Koblish et al. Jul 2005 B2
6939346 Kannenberg et al. Sep 2005 B2
6954977 Maguire et al. Oct 2005 B2
7027869 Danek et al. Apr 2006 B2
7043307 Zelickson et al. May 2006 B1
7104987 Biggs et al. Sep 2006 B2
7104990 Jenkins et al. Sep 2006 B2
7118568 Hassett et al. Oct 2006 B2
7122033 Wood Oct 2006 B2
7131445 Amoah Nov 2006 B2
7186251 Malecki et al. Mar 2007 B2
7198635 Danek et al. Apr 2007 B2
7200445 Dalbec et al. Apr 2007 B1
7241295 Maguire Jul 2007 B2
7255693 Johnston et al. Aug 2007 B1
7264002 Danek et al. Sep 2007 B2
7266414 Cornelius et al. Sep 2007 B2
7273055 Danek et al. Sep 2007 B2
7542802 Biggs et al. Jun 2009 B2
7556624 Laufer et al. Jul 2009 B2
7740017 Danek et al. Jun 2010 B2
7992572 Danek et al. Aug 2011 B2
8251070 Danek et al. Aug 2012 B2
20020091379 Danek et al. Jul 2002 A1
20030050631 Mody et al. Mar 2003 A1
20030065371 Satake Apr 2003 A1
20030069570 Witzel et al. Apr 2003 A1
20030159700 Laufer et al. Aug 2003 A1
20030187430 Vorisek Oct 2003 A1
20030236455 Swanson et al. Dec 2003 A1
20040031494 Danek et al. Feb 2004 A1
20040153056 Muller et al. Aug 2004 A1
20040182399 Danek et al. Sep 2004 A1
20040249401 Rabiner et al. Dec 2004 A1
20050010270 Laufer Jan 2005 A1
20050096644 Hall et al. May 2005 A1
20050171396 Pankratov et al. Aug 2005 A1
20050193279 Daners Sep 2005 A1
20050203503 Edwards et al. Sep 2005 A1
20050240176 Oral et al. Oct 2005 A1
20050251128 Amoah Nov 2005 A1
20060062808 Laufer et al. Mar 2006 A1
20060079887 Buysse et al. Apr 2006 A1
20060089637 Werneth et al. Apr 2006 A1
20060135953 Kania et al. Jun 2006 A1
20060137698 Danek et al. Jun 2006 A1
20060247617 Danek et al. Nov 2006 A1
20060247618 Kaplan et al. Nov 2006 A1
20060247619 Kaplan et al. Nov 2006 A1
20060247726 Biggs et al. Nov 2006 A1
20060247727 Biggs et al. Nov 2006 A1
20060247746 Danek et al. Nov 2006 A1
20060254600 Danek et al. Nov 2006 A1
20060278244 Danek et al. Dec 2006 A1
20060282071 Utley et al. Dec 2006 A1
20070074719 Danek et al. Apr 2007 A1
20070083194 Kunis et al. Apr 2007 A1
20070083197 Danek et al. Apr 2007 A1
20070100390 Danaek et al. May 2007 A1
20070102011 Danek et al. May 2007 A1
20070106292 Kaplan et al. May 2007 A1
20070106296 Laufer et al. May 2007 A1
20070106348 Laufer May 2007 A1
20070118184 Danek et al. May 2007 A1
20070118190 Danek et al. May 2007 A1
20070123958 Laufer May 2007 A1
20070123961 Danek et al. May 2007 A1
20070129720 Demarais et al. Jun 2007 A1
20080004596 Yun et al. Jan 2008 A1
20080097424 Wizeman et al. Apr 2008 A1
20080255642 Zarins et al. Oct 2008 A1
20090018538 Webster et al. Jan 2009 A1
20090030477 Jarrard Jan 2009 A1
20090043301 Jarrard et al. Feb 2009 A1
20090069797 Danek et al. Mar 2009 A1
20090112203 Danek et al. Apr 2009 A1
20090143705 Danek et al. Jun 2009 A1
20090143776 Danek et al. Jun 2009 A1
20090192505 Askew et al. Jul 2009 A1
20090192508 Laufer et al. Jul 2009 A1
20090306644 Mayse et al. Dec 2009 A1
Foreign Referenced Citations (49)
Number Date Country
195 29 634 Feb 1997 DE
189329 Jun 1987 EP
286145 Oct 1988 EP
280225 Mar 1989 EP
286145 Oct 1990 EP
282225 Jun 1992 EP
908713 Apr 1999 EP
908150 May 2003 EP
768091 Jul 2003 EP
1297795 Aug 2005 EP
2659240 Jul 1997 FR
2233293 Jan 1991 GB
2233293 Feb 1994 GB
59167707 Sep 1984 JP
7289557 Nov 1995 JP
9047518 Feb 1997 JP
9243837 Sep 1997 JP
10026709 Jan 1998 JP
2 053 814 Feb 1996 RU
2 091 054 Sep 1997 RU
545358 Feb 1977 SU
WO-8911311 Nov 1989 WO
WO-9502370 Jan 1995 WO
WO-9510322 Apr 1995 WO
WO-9604860 Feb 1996 WO
WO-9610961 Apr 1996 WO
WO-9732532 Sep 1997 WO
WO-9733715 Sep 1997 WO
WO 9737715 Oct 1997 WO
WO-9740751 Nov 1997 WO
WO-9844854 Oct 1998 WO
WO-9852480 Nov 1998 WO
WO-9856234 Dec 1998 WO
WO-9856324 Dec 1998 WO
WO 9903413 Jan 1999 WO
WO-9858681 Mar 1999 WO
WO-9913779 Mar 1999 WO
WO-9932040 Jul 1999 WO
WO-9934741 Jul 1999 WO
WO-9944506 Sep 1999 WO
WO-9945855 Sep 1999 WO
WO-9964109 Dec 1999 WO
WO-0051510 Sep 2000 WO
WO-0062699 Oct 2000 WO
WO-0103642 Jan 2001 WO
WO-0232333 Apr 2002 WO
WO-0232334 Apr 2002 WO
WO-2009082433 Jul 2009 WO
WO-2009137819 Nov 2009 WO
Non-Patent Literature Citations (68)
Entry
Ivanyuta, O. M. et al., “Effect of Low-Power Laser Irradiation of Bronchial Mucosa on the State of Systemic and Local Immunity in Patients With Chronic Bronchitis,” Problemy Tuberkuleza, 6:26-29 (1991).
Provotorov, V. M. et al., “Clinical Efficacy of Treatment of Patients With Nonspecific Pulmonary Diseases by Using Low-Power Laser Irradiation and Performing Intrapulmonary Drug Administration,” Terapevticheskii Arkhiv, 12:62:18-23 (1991).
Vorotnev, A. I. et al., “Treatment of Chronic Obstructive Bronchitis Patients Using a Low-Power Laser at a General Rehabilitation Center,” Terapevticheskii Arkhiv, 3:17-19 (1997).
Vasilotta, P. L. et al., “I-R Laser: A New Therapy in Rhino-Sino-Nasal Bronchial Syndrome with Asthmatic Component,” Americal Society for Laser medicine and Surgery abstracts, date unknown, p. 74.
Shesterina, M. V. et al., Effect of laser therapy on immunity in patients with bronchial asthma and pulmonary tuberculosis, 1993, pp. 23-26.
An S. S., et al., “Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma,” European Respiratory Journal, 2007, 29 (5), 834-860.
Bel, et al., ““Hot stuff”: bronchial thermoplasty for asthma,” American Journal of Respiratory and Critical Care Medicine, 2006, 173, 941-943.
Brown R. H., et al., “Effect of bronchial thermoplasty on airway distensibility,” European Respiratory Journal, 2005, 26 (2), 277-282.
Brown R. H., et al., “In vivo evaluation of the effectiveness of bronchial thermoplasty with computed tomography,” Journal of Applied Physiology, 2005, 98, 1603-1606.
Chhajed P., et al., “Will there be a role for bronchoscopic radiofrequency ablation?,” J Bronchol, 2005, 12 (3), 184-186.
Co-pending U.S. Appl. No. 12/640,644, filed Dec. 17, 2009, Inventor Jerry Jarrard.
Co-pending U.S. Appl. No. 12/727,156, filed Mar. 18, 2010, Inventor Danek et al.
Co-pending U.S. Appl. No. 12/765,704 filed Apr. 22, 2010, Inventor Danek et al.
Cox G., et al., “Asthma Control during the Year after Bronchial Thermoplasty,” The New England journal of medicine, 2007, 356 (13), 1327-1337.
Cox G., et al., “Bronchial Thermoplasty for Asthma,” American Journal of Respiratory and Critical Care Medicine, 2006, 173, 965-969.
Cox G., et al., “Bronchial Thermoplasty: Long-Term Follow-Up and Patient Satisfaction,” Chest, 2004, 126 (4), 822s.
Cox G., et al., “Bronchial Thermoplasty: One-Year Update, American Thoracic Society Annual Meeting,” Am J Respir Crit Care Med, 2004, 169, A313.
Cox G., et al., “Clinical Experience With Bronchial Thermoplasty for the Treatment of Asthma,” Chest, 2003, 124, 106S.
Cox G., et al., “Development of a Novel Bronchoscopic Therapy for Asthma,” Journal of Allergy and Clinical Immunology, 2003, 113 (2), S33.
Cox G., et al., “Early Clinical Experience with Bronchial Thermoplasty for the Treatment of Asthma, American Thoracic Society Annual Meeting,” 2002, 1068.
Cox G., et al., “Impact of bronchial thermoplasty on asthma status: interim results from the AIR trial.European Respiratory Society Annual Meeting. Munich, Germany,” 2006, 1 page.
Cox G., et al., “Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations,” European Respiratory Journal, 2004, 24, 659-663.
Danek C. J., et al., “Asthma Intervention Research (AIR) Trial Evaluating Bronchial Thermoplasty™: Early Results, American Thoracic Society Annual Meeting,” 2002, 1 page.
Danek C. J., et al., “Bronchial thermoplasty reduces canine airway responsiveness to local methacholine challenge, American Thoracic Society Annual Meeting,” 2002, 1 page.
Danek C. J., et al., “Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs,” J Appl Physiol, 2004, 97, 1946-1953.
Erle C. H., et al., “Botulinum toxin: a novel therapeutic option for bronchial asthma?,”Medical Hypotheses, 2006, 66, 915-919.
Global Strategy for Asthma Management and Prevention, 2002, 192 Pages Total.
James, et al., “The Mechanics of Airway Narrowing in Asthma,” Am. Rev. Respir. Dis., 1989, 139, 242-246.
Janssen L. J., “Asthma therapy: how far have we come, why did we fail and where should we go next?,” Eur Respir J, 2009, 33, pp. 11-20.
Julian Solway M. D., et al., “Airway Smooth Muscle as a Target for Asthma Therapy,” The New England journal of medicine, 2007, 356 (13), 1367-1369.
Kitamura S., “Color Atlas of Clinical Application of Fiberoptic Bronchoscopy,” 1990, Year Book Medical Publishers, 17.
Kraft M., “The distal airways: are they Important in asthma?,” European Respiratory, 1999, 1403-1417.
Laviolette, et al., “Asthma Intervention Research (Air) Trial: Early Safety Assessment of Bronchial Thermoplasty,” Am J Respir Crit Care Med, 2004, 169, A314.
Leff, et al., “Bronchial Thermoplasty Alters Airway Smooth Muscle and Reduces Responsiveness in Dogs: A Possible Procedure for the Treatment of Asthma, American Thoracic Society Annual Meeting,” 2002, 1 page.
Lombard, et al., “Histologic Effects of Bronchial Thermoplasty of Canine and Human Airways, American Thoracic Society Annual Meeting,” 2002, 1 page.
Mayse M. L., et al., “Clinical Pearls for Bronchial Thermoplasty,” J Bronchol, 2007, 14 (2), 115-123.
Miller J. D., et al., “A Prospective Feasibility Study of Bronchial Thermoplasty in the Human Airway,” 2005, 127, 1999-2006.
Miller J. D., et al., “Bronchial Thermoplasty is Well Tolerated by Non-Asthmatic Patients Requiring Lobectomy, American Thoracic Society Annual Meeting,” 2002, 1 page.
Notice of final Rejection, Japanese Patent Application No. 2000-553172, dated Sep. 2, 2008, 5 pages.
PCT International search report for application No. PCT/US00/05412 mailed on Jun. 20, 2000, 2 pages.
PCT International search report for application No. PCT/US00/18197 mailed on Oct. 3, 2000, 1 page.
PCT International search report for application No. PCT/US00/28745 mailed on Mar. 28, 2001, 6 pages.
PCT International search report for application No. PCT/US01/32321 mailed on Jan. 18, 2002, 2 pages.
PCT International search report for application No. PCT/US98/03759 mailed on Jul. 30, 1998, 1 page.
PCT International search report for application No. PCT/US98/26227 mailed on Mar. 25, 1999, 1 page.
PCT International search report for application No. PCT/US99/00232 mailed on Mar. 4, 1999, 1 page.
PCT International search report for application No. PCT/US99/12986 mailed on Sep. 29, 1999, 1 page.
Peter K. Jeffery, “Remodeling in Asthma and Chronic Obstructive Lung Disease,” American Journal of Respiratory and Critical Care Medicine, 2001, 164 (10), 13516.
Rubin, et al., “Bronchial thermoplasty improves asthma status of moderate to severe perisstent asthmatics over and above current standard-of-care, American College of Chest Physicians,” 2006, 2 pages.
Seow C. Y., et al., “Signal Transduction in Smooth Muscle Historical perspective on airway smooth muscle: the saga of a frustrated cell,” J Appl Physiol, 2001, 91, 938-952.
Stephanie A.Shore, “Airway Smooth Muscle in Asthma—Not Just More of the Same,” N Engl J Med, 2004, 351 (6), 531-532.
Sterk P. J., et al., “Heterogeneity of airway hyperresponsiveness: time for unconventional, but traditional, studies,” J Appl Physiol, 2004, 96, 2017-2018.
Toma, et al., “Brave new world for interventional bronchoscopy,” Thorax, 2005, 60, 180-181.
Trow T., “Clinical Year in Review I Diagnostic Imaging, Asthma, Lung Transplantation, and Interventional Pulmonology,” Proceedings of the American Thoracic Society, 2006, 3, 553-556.
UNSW Embryo-Respiratory System [online], Embryology, 2007, [retrieved on Dec. 10, 2007]. Retrieved from the internet: (URL:http://embryology.med.unsw.edu.au/Refer/respire/sclect.htm).
Wayne Mitzner, “Airway Smooth Muscle the appendix of the Lung,” American Journal of Respiratory and Critical Care Medicine, 2004, 169, 787-790.
Wayne Mitznerl, “Bronchial Thermoplasty in Asthma,” Allergology International, 2006, 55, 225-234.
Wilson S. R., et al., “Global assessment after bronchial thermoplasty: the patients perspective,” Journal of Outcomes Research, 2006, 10, 37-46.
Wizeman, et al., “A Computer Model of Thermal Treatment of Airways by Radiofrequency (RF) Energy Delivery, American Thoracic Society Annual Meeting,” 2007, 1 page.
Co-pending U.S. Appl. No. 09/244,173, filed Feb. 4, 1999, Inventor Laufer et al.
Co-pending U.S. Appl. No. 09/436,455, filed Nov. 8, 1999, Inventor Danek et al.
Co-pending U.S. Appl. No. 09/095,323, filed Jun. 10, 1998, Inventor Laufer.
Simon R. Johnson et al., Synthetic Functions of Airway Sinooth Muscle in Asthma, Trends Pharmacol. Sci., Aug. 1997, 18(8), 288-292.
Macklem P.T., Mechanical Factors Determining Maximum Bronchoconstriction, European Respiratory Journal, Jun. 1989, 6, 516s-519s.
James C. Hogg, The Pathology of Asthma, APMIS, Oct. 1997, 105(10), 735-745.
Dierkesmann et al., Indication and Results of Endobronchial Laser Therapy, Lung, 1990, 168, 1095-1102.
Netter F.H., Respiratory System: A Compilation of Paintings Depicting Anatomy and Embryologyl Physiology, Pathology, Pathophysiology, and Clinical Features and Treatment of Diseases, in the CIBA Collection of Medical Illustrations M.B. Divertie, ed., Summit: New Jerse, 1979, vol. 7, 119-135.
Wiggs B.R. et al., On the Mechanism of Mucosal Folding in Normal and Asthmatic Airways, J. Appl. Physiol., Dec. 1997, 83(6), 1814-1821.
Related Publications (1)
Number Date Country
20060278243 A1 Dec 2006 US
Continuations (2)
Number Date Country
Parent 10640967 Aug 2003 US
Child 11421444 US
Parent 09535856 Mar 2000 US
Child 10640967 US
Continuation in Parts (6)
Number Date Country
Parent 09296040 Apr 1999 US
Child 09535856 US
Parent 09095323 Jun 1998 US
Child 09296040 US
Parent 11421444 US
Child 09296040 US
Parent 09436455 Nov 1999 US
Child 11421444 US
Parent 09095323 Jun 1998 US
Child 09436455 US
Parent 09349715 Jul 1999 US
Child 09095323 US